AU Patent

AU2020203531B2 — Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting b2 adrenergic receptor agonists and associated methods and systems

Assigned to Pearl Therapeutics Inc · Expires 2023-04-27 · 3y expired

What this patent protects

Compositions, methods and systems are provided for pulmonary delivery of long acting muscarinic antagonists and long-acting P2 adrenergic receptor agonists via a 5 metered dose inhaler. In particular embodiments, the compositions include a suspension medium, active agent partic…

USPTO Abstract

Compositions, methods and systems are provided for pulmonary delivery of long acting muscarinic antagonists and long-acting P2 adrenergic receptor agonists via a 5 metered dose inhaler. In particular embodiments, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.

Drugs covered by this patent

Patent Metadata

Patent number
AU2020203531B2
Jurisdiction
AU
Classification
—
Expires
2023-04-27
Drug substance claim
No
Drug product claim
No
Assignee
Pearl Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.